🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — March 23, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, machinery, and adjacent sectors), key themes include robust M&A and spin-off activity (e.g., Honeywell Aerospace spin, Sealed Air acquisition), SPAC extensions/mergers, and mixed financial results with revenue growth in 7/15 reporting companies averaging +35% YoY (e.g., Arbutus +128%, SolarEdge +31%) offset by persistent losses and cash burn in biotechs/small caps. Period-over-period trends show margin improvements in 5 cases (e.g., Bionano gross margin to 46% from 1%, Cato FY SG&A to 35% from 36%), but declines in others (Core Labs op income -3.6% YoY, Cabaletta net loss +45%). Capital allocation leans toward buybacks/repurchases (Slide $125M, Guardian 1.8M shares) and debt refinancings (Hewlett Packard $2B notes, Waters $3.5B), signaling confidence amid high interest environments. Forward-looking catalysts cluster in 2H 2026 (Phase 3 trials, Nasdaq compliances), with positive regulatory clearances (Faraday SEC no-action) removing overhangs. Portfolio-level, industrials show relative strength in cap allocation vs. small-cap dilution risks, positioning sector for consolidation-driven alpha.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 23, 2026

The five filings for the USA S&P 500 Energy intelligence stream feature routine proxy materials from non-energy firms (Halozyme Therapeutics in biotech, CommScope in telecom, and AParadise SPAC), highlighting a potential data mismatch but analyzed for governance insights; all exhibit neutral sentiment with materiality ranging 2-6/10 and no substantive financial or operational enriched data like YoY/QoQ trends, insider trading, capital allocation, or M&A details disclosed. Overarching themes include upcoming virtual annual meetings in early May 2026 for director elections, advisory compensation votes, and auditor ratifications, signaling standard proxy season kickoff without period-over-period financial comparisons or forward-looking guidance changes. No portfolio-level trends in revenue growth, margins, or ratios identifiable due to lack of metrics; SPAC PFIC statement provides minor positive ordinary earnings of $0.000605 per-share per-day for FY2025 with no capital gains/distributions. Critical developments center on scheduled AGMs as near-term catalysts for governance votes, with low proxy costs (e.g., CommScope $11k) indicating efficient shareholder engagement. Market implications are minimal for energy sector but offer tactical opportunities in voting participation and monitoring board stability across filings.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 23, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related services), dominant themes include elevated M&A activity (10+ filings on mergers like CECO/Thermon, Victory/Janus Henderson, Two Harbors bidding war), mixed 2025 financial performance with revenue growth in 7/15 10-Ks averaging +25% YoY (e.g., Finwise +31% assets, SUNation +26%) but declines in 8/15 averaging -20% (e.g., Aterian -30%, Ashford -6%), and proactive capital allocation via buybacks/dividends (Coeur $750M program, News Corp $1B authorization). Period-over-period trends show margin compression in 6/12 detailed cos (avg -150bps, e.g., Aterian gross margin 568bps drop) offset by strong growth in niche banking/insurance (Finwise NIM 9.23%, Progressive 12% premiums). Insider activity sparse but notable 10b5-1 plans (Avalo execs up to 471k shares) signal potential selling pressure; forward guidance largely raised (CECO +23% rev, Coeur gold prod +80%). Portfolio implications: overweight M&A targets/defenses (Two Harbors $10.75/share bid), monitor cyber/regulatory risks (Heritage incident, Volato delisting), with catalysts clustered Q2-H2 2026 (Phase trials, earnings). Overall bullish on capital returners, cautious on high-burn biotechs/hospitality.

31 high priority 19 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 23, 2026

Across 50 SEC filings from March 23, 2026, a dominant theme is robust corporate financing activity with 18 companies announcing new or amended credit facilities, debt refinancings, or equity offerings (e.g., $10M RenovoRx raise, $750M Ormat notes, $150M Unusual Machines offering), signaling improved liquidity and access to capital amid maturing prior debts. Leadership transitions dominate 22 filings, mostly orderly (e.g., promotions at Virtuix, retirements at Oil States), though some raise concerns like CEO departures at Mesa Labs and SiriusPoint. M&A and divestitures advanced positively (Coeur Mining acquisition boosting 2026 gold production 80% YoY to 680-815koz, Everest Group sale), alongside capital returns (Coeur $750M buyback + inaugural dividend). Period-over-period highlights include Sutro Biopharma's FY2025 revenue +65% YoY to $102.5M, net loss -16% to $191.1M, and RenovoRx's $900k revenue in 9M2025; however, cash burns persist in biotechs. Sector patterns show mining/energy strength (production guidance up, refinancings), financial/healthcare financing surge, but liquidity strains in smaller caps (MSP Recovery advances). Implications: Bullish for refinancings extending maturities (avg to 2029+), watch biotech catalysts, portfolio tilt to miners with buybacks.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 23, 2026

Across these 10 filings from the S&P 500 Technology stream (including adjacent telecom, SPACs, and outliers like banking), dominant themes include active M&A/SPAC activity (3/10 filings) signaling consolidation, capital raise preparations via shelves and ATM offerings (3/10), and mixed FY2025/2026 financials with revenue growth but profitability challenges. Period-over-period trends show robust top-line growth in Planet Labs (+26% YoY revenue to $307.7M, Adj EBITDA to +$15.5M from -$10.6M) and Richmond Mutual (+23.4% net income to $11.6M, NIM to 2.97% from 2.67%), contrasted by asset quality deterioration (RMBI NPAs to 1.14% from 0.45%) and widened losses (PL net loss to $246.9M from $123.2M). Critical developments like TETE's SPAC merger proxy (low $142K trust signaling high redemptions) and RMBI's bank merger (38% ownership stake post-deal) imply dilution risks and arbitrage potential. Sector implications point to funding pressures amid growth investments, with Planet's deferred revenue surge (+165% to $248.1M) highlighting backlog strength. Portfolio-level, 2/3 detailed financials show margin stability/mixed (PL gross margin -100bps to 56%) but liquidity improvements (PL cash +94% to $229.4M).

5 high priority 5 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 23, 2026

Across 12 filings from NASDAQ-100 related entities, dominant themes include regulatory relief (e.g., Faraday Future's SEC investigation closure), banking M&A (RMBI-Farmers merger valued at $82.4M), and frequent dilution via ATM/shelf offerings (Imunon +$7M to $17M, IBS +$3.97M, Comtech $125M shelf), signaling capital needs in small caps. Period-over-period trends show RMBI's standout net income +23.4% YoY to $11.6M and NIM expansion +30bps to 2.97%, but offset by non-performing assets surging to 1.14% from 0.45%; no broad portfolio growth trends emerge due to limited financial disclosures. Critical developments like Faraday's Nasdaq 180-day compliance window (from Mar 20, 2026) and Intel's proxy highlighting 2025 reinvention under CEO Lip-Bu Tan position for catalysts. Portfolio patterns reveal mixed sentiment (positive in 4/12, neutral 6/12, mixed 2/12) with AI/EV focus (Faraday robotics sales 2026 start) and SPAC mergers (TETE low $142k trust signaling redemptions). Implications favor tactical plays in cleared overhangs and mergers, but caution on dilutions and asset quality deterioration.

6 high priority 6 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 23, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip adjacent with SPAC/M&A focus), dominant themes include heightened M&A and de-SPAC activity (10+ filings: Thermon/CECO, Two Harbors competing bids at $10.70-$10.75/share, Victory/Janus, ReserveOne), mixed financial performance with 7/15 reporting companies showing YoY net income growth or loss narrowing (e.g., AbbVie revenues +8.5% operationally, Finwise +26%, Cato FY loss -67% to $5.9M), but biotechs facing cash burn (Avalo cash -88% to $15.9M, Cabaletta -19% to $133.6M). Period-over-period trends reveal revenue growth averaging +15% YoY in outperformers (Progressive premiums +12%, CECO +39%), offset by margin pressures (Finwise NIM -76 bps to 9.23%) and elevated provisions/expenses; capital allocation leans shareholder-friendly with repurchases (Slide $125M), dividends (AbbVie to $1.73/share), and buybacks implied in strong cash flows. Honeywell's debt tender supports Aerospace spin-off, Faraday Future clears SEC overhang, signaling blue-chip stability amid small-cap volatility. Portfolio implications: overweight M&A targets for premiums, monitor biotech catalysts (Avalo/Cabaletta data Q2/1H26), avoid delisting risks (Volato); overall positive sentiment in 18/50 filings drives near-term upside in select names.

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 23, 2026

Across 50 SEC filings dated March 23, 2026, key themes include mixed financial performance in 2025 10-Ks with 7/15 reporting revenue growth (avg +30% YoY in winners like Finwise +31% assets, Idaho Strategic +65% concentrate sales) contrasted by sharp declines in 5/15 (avg -20% YoY, e.g., Aterian -30%, Ashford Hospitality -6% revenue, -200% net loss widening); robust M&A progress in 5 filings (Thermon/CECO synergies >$40M, Sealed Air clearances, Mission Produce/Calavo proxies); financing positives (Nortech $15M revolver to 2029, Ormat $750M notes for buybacks/debt repurchase); biotech catalysts (Apogee Phase 2 success, Faraday SEC clearance); and neutral/low-materiality ABS compliance (9/10 trusts). Portfolio-level trends show margin resilience in growth names (Idaho gross margin +1150 bps to 62%) but compression elsewhere (Core Labs op income -4%, Aterian gross -530 bps); capital allocation favors repurchases (Honeywell tender $10B notes, News Corp $1B program, Ormat $25M stock buybacks). Critical implications: monitor M&A closes/delays (April 2026 Sealed Air), delisting risks (Volato NYSE deficiency), and Q2 2026 catalysts (Apogee APEX Part B, Avalo LOTUS trial). Sector outliers highlight mining/gold strength vs consumer product weakness, with overall neutral-to-mixed sentiment (22 neutral, 12 mixed). Actionable now: Favor growth outliers like Finwise BaaS (+160% non-interest income), avoid hospitality drags.

36 high priority 14 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 23, 2026

Across 43 filings in the USA S&P 500 Healthcare stream (with some cross-sector inclusions), proxy statements dominate (e.g., AbbVie, Stryker, Baxter), signaling peak proxy season with governance enhancements like eliminating supermajority voting (AbbVie, Regions) and board refreshes. Healthcare leaders show robust 2025 performance: AbbVie net revenues +8.5% YoY to $61.2B (Growth Platform +19.6% to $56.6B, Skyrizi +50%, Rinvoq +40%), while M&A accelerates with Abbott's $105/share cash acquisition of Exact Sciences completed March 23, 2026. Period-over-period trends reveal revenue growth averaging +10-20% YoY in key reporters (AbbVie +8.5%, Yunhong +10%, Sparta +71% 9M), but mixed profitability with losses widening in biotechs/small caps (Bally's -$666M Successor, Procaccianti net income -10% YoY to $1.9M). Cyber risks emerge (Stryker incident contained but ongoing probe; Heritage unauthorized access), biotech trials positive (Artelo ART27.13 +6.38% weight gain Phase 2a), and capital allocation favors dividends (AbbVie quarterly $1.73/share, +485% TSR decade). Portfolio implications: Bullish on pharma/devices growth/M&A, cautious on cyber/biotech volatility; 5/10 healthcare filings highlight strong op cash flows ($19B AbbVie) vs sector margin stability.

23 high priority 20 medium 43 total filings
· daily

Global High-Priority Regulatory Events — March 23, 2026

Across 50 filings, a dominant theme is distress in Indian companies with 7 insolvency-related updates (e.g., Educomp fresh CIRP, AGS/Vas/Punj Lloyd/RHFL meetings), signaling prolonged corporate restructurings amid neutral RBI liquidity injections (~₹65K Cr net). US filings show mixed 10-K results: revenue growth in mining/energy (Idaho Strategic +65% YoY, Finwise NI +26%) offset by declines (Aterian -30%, Ashford -6%, Core Labs flat), with positive M&A catalysts (Coeur/New Gold acquisition boosting 2026 gold prod +80%, Thermon/CECO merger synergies >$40M). Capital allocation trends favor shareholder returns (Coeur $750M buyback + dividend, Ormat $25M stock repurchases), while ABS trusts (9 filings) confirm routine compliance with no material issues. Portfolio-level, margins compressed in hospitality/tech (Ashford EBITDAre -6%), but gold miners outperformed on price tailwinds ($3,583/oz realized). Critical implications: monitor Indian insolvency resolutions for turnaround alpha, US M&A for consolidation plays, and delisting risks (Volato). Forward catalysts cluster in late March/April 2026 (NCLT hearings, earnings, compliance plans).

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 23, 2026

The IPO Pipeline stream shows robust activity with four filings on March 23, 2026, including three S-1s for share registrations/resales and one S-4 for a banking merger, signaling heightened pre-IPO and follow-on preparations amid a transitional market. AI Era Corp. (formerly AB International) generated $1.16M in new AI licensing revenue post-November 30, 2025, marking a pivot from streaming divestiture, while MobbQuest and AEVEX highlight microcap risks with going concern doubts and control weaknesses. Period-over-period, AI Era's revenue surged from zero historical base to $1.16M in ~4 months, contrasting MobbQuest's zero revenue and $11K deficit. The RMBI-Farmers merger offers consolidation value at $82.4M aggregate (~$44.71/share), positive amid sector M&A. Overarching themes include high-risk microcap IPO aspirants (3/4 filings) with low cash ($11.8K-$48K) and deficits ($10M+ in two cases), versus stable banking deal; implications point to volatile pipeline with merger as outlier stability.

4 high priority 4 total filings
· daily

US Earnings Financial Results SEC Filings — March 23, 2026

Across 50 US SEC filings for FY2025 (ended Dec 31, 2025), sentiment is predominantly mixed (28/50), with neutral ABS trusts (12/50) and negative outliers in consumer/hospitality sectors; revenue trends show sharp declines in consumer goods (avg -30% YoY for Aterian, Solo Brands) offset by growth in mining/biotech (e.g., Idaho Strategic +64.6% YoY, Arbutus +128% YoY). Net losses widened in 18 companies (avg +45% YoY in biotechs like Cabaletta, Surrozen), but narrowed in 12 (e.g., Xilio -40%, Sutro -16%); cash positions improved in 15 firms via financing/IPOs, but burned in biotech heavy-hitters. SPACs (Cartesian, SilverBox, Bold Eagle, TGE) reported strong trust interest income (+300-400% YoY) amid negative equity, signaling de-SPAC catalysts. Capital allocation leaned toward debt reduction (Core Labs -13% net debt, Ultralife -12%) over dividends/buybacks; insider activity limited to 10b5-1 selling plans (Avalo, Pyxis) indicating caution. Portfolio-level: Biotech R&D surges (+30-180% YoY) drive losses but fuel pipelines; consumer margin resilience amid sales drops offers turnaround potential; ABS compliance uniform/neutral implies stable securitizations.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 23, 2026

Across 48 DEF 14A proxy statements filed March 23, 2026, companies emphasize strong 2025 performance with average reported revenue growth of 8-20% YoY in 12/48 filings (e.g., AbbVie +8.5% to $61.2B, Gallagher +20.7% to $13.7B), robust capital returns including dividend increases (AbbVie to $1.73/share, Kimberly-Clark 54th consecutive year), and buybacks (RLJ $28.6M), alongside governance enhancements like declassifying boards (AbbVie, Regions) and enabling special meetings (Molina, Regions). Key trends include outperformance vs. benchmarks (Progressive 1.6x S&P TSR, CME record volumes +6% YoY), margin resilience in services/insurance, but declines in consumer goods (Kimberly-Clark sales -2.1% YoY) and hospitality (RLJ constrained RevPAR). Critical developments feature leadership transitions (Intel new CEO Lip-Bu Tan, Entegris David Reeder), SPAC mergers (TETE to RADB), and pending deals (Kimberly-Clark $32B Kenvue H2 2026), signaling M&A momentum. Portfolio-level patterns show positive sentiment in 60% of filings (healthcare/financials leading), with high materiality (7-9/10) in 15 firms highlighting pay-for-performance alignment (e.g., Enpro 130.5% payouts). Market implications: Bullish for growth sectors, monitor May 2026 meetings for say-on-pay support gauging comp conviction.

48 high priority 48 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 23, 2026

Across 46 filings in the USA Corporate Distress & Bankruptcy stream (32 new), the dominant theme is aggressive liquidity bolstering via 18+ new/expanded credit facilities, 12 equity/debt raises, and 8 refinancings extending maturities (avg ~3yrs) and cutting rates (e.g., California Resources 8.25% to 7%), signaling stabilization rather than deepening distress. Period-over-period highlights include Sutro Biopharma's FY2025 revenue +65% YoY to $102.5M, R&D -34% to $166.4M, net loss improved -16% to $191.1M; RenovoRx $900k rev in 9M2025 from commercialization. Insider conviction strong in RenovoRx (mgmt/board participation), Empery Digital ($200M buybacks at $5.92 avg). Critical developments: Volato NYSE delisting risk (equity < $2M/4M), MSP Recovery liquidity crunch ($75k advance + CRO). Portfolio trends: Positive sentiment 60% (28/46), financing materiality avg 8/10; bearish outliers in microcaps. Implications: Short-term survival plays dominant, alpha in refi beneficiaries and biotech catalysts, monitor delistings for shorts.

46 high priority 46 total filings
· daily

US SEC Trading Suspension Halt Orders — March 23, 2026

Across the single filing in the USA Trading Suspensions stream, Volato Group, Inc. (SOAR) faces severe NYSE American delisting risk due to stockholders’ equity falling below $2.0M (losses in two of three recent fiscal years) and $4.0M (losses in three of four recent fiscal years), signaling prolonged financial distress with no provided YoY/QoQ recovery trends. Negative sentiment dominates with 9/10 materiality, highlighting non-compliance under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide. No immediate trading suspension impacts Class A Common Stock (SOAR) on NYSE American, but warrants (SOARW) already trade on OTC Markets, foreshadowing potential further liquidity erosion. Absent enriched data on insider activity shows no management buying conviction, while forward-looking compliance deadlines (plan by April 16, 2026; regain standards by December 17, 2026) create a high-stakes catalyst calendar. Capital allocation details unavailable, but sustained losses imply strained shareholder returns with no dividends or buybacks noted. Portfolio-level theme: isolated small-cap aviation player exemplifies regulatory vulnerability amid equity deficits, urging immediate position reviews.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 23, 2026

Across 38 US SEC filings dated March 23, 2026, focused on boardroom changes, a dominant theme emerges of strategic leadership successions and transitions, with 12 positive sentiment cases (e.g., orderly CEO handovers in 4 Gladstone entities), 15 neutral director retirements/resignations, and 5 negative/mixed signals amid operational challenges like missed milestones. No broad YoY revenue growth trends reported, but period comparisons highlight BioAtla's 2025 bonus misses (0% payout) vs retention incentives for 2026 milestones, contrasting with reaffirmed FY26 outlooks (Cardinal Health). Insider-like conviction shines in internal promotions (e.g., Oil States CFO to CEO, Crawford interim to permanent) signaling stability, while 7 CEO/CFO departures raise continuity risks. Portfolio-level pattern: Biotech/healthcare (8 filings) shows 50% turnover rate with mixed milestones; finance/REITs (10 filings) emphasize governance separations (Chairman/CEO split). Forward catalysts cluster Q2 2026 (earnings, AGMs, milestones), implying near-term volatility but alpha in smooth transitions. Capital allocation leans retention bonuses/RSUs over buybacks, with no dividend/split changes noted.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — March 23, 2026

The 10 filings reveal heightened US M&A and takeover activity dominated by SPACs (7/10 filings), with extensions, approvals, and high redemptions signaling persistent deal momentum amid liquidity pressures; actual sector M&A includes mining consolidation (Coeur-New Gold boosting 2026 gold production guidance 80% YoY from 419k oz to 680-815k oz), reinsurance divestiture (FG Nexus), crowdfunding expansion (StartEngine-Vinovest adding $140-150M AUM), and governance tweaks post-acquisition (Exact Sciences). Period-over-period trends show SPAC trust deposits for extensions (YHN $150k) contrasting low balances (TETE $142k signaling redemptions), while Coeur's reserves integration extends mine life to 2032-2035 with strong FCF projections. Capital allocation shines in Coeur's $750M buyback and inaugural $0.02/share dividend vs prior $400M facility upgrade to $1B revolver. Overarching themes: SPAC resilience via extensions/name changes (Goldenstone to Chi Special) but delisting risks (Bayview); positive sentiment in 6/10 filings drives alpha in mining/alts, mixed in SPACs due to redemptions (Crane 19.4M shares/$201M). Portfolio implication: Favor completed M&A with guidance upside over pre-merger SPACs; monitor March 26-31 catalysts for volatility.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 23, 2026

Across 50 overnight SEC filings, dominant themes include mixed 2025 full-year results in 10-Ks with revenue growth in select miners/banks (e.g., Idaho Strategic +64.6% YoY, Finwise +26% net income) offset by declines in consumer/hospitality (Aterian -30.4%, Ashford -5.8% revenue), alongside M&A progress (Thermon/CECO synergies >$40M, Sealed Air regulatory clearances), debt refinancings (Nortech $15M revolver to 2029, Ormat $750M notes), and biotech catalysts (Apogee 52-week data supporting Phase 3 in 2H2026). Portfolio-level trends show 7/15 10-Ks with revenue growth averaging +28% YoY but 5 with net losses widening (avg +45%), margin compression in 4/10 (avg -200bps), and improving balance sheets in 6/10 via debt reduction/cash builds. Positive capital allocation signals like News Corp $1B buybacks and Ormat stock repurchases contrast cyber risks (Heritage incident) and delisting threats (Volato). Critical developments: Faraday Future SEC clearance removes overhang; Apogee AD data positions for $50B market. Implications favor energy/mining longs, M&A arbitrage, caution hospitality/consumer shorts amid pre-market positioning.

36 high priority 14 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 22, 2026

Tayo Rolls Limited (Stock Code: 504961) exemplifies a high-priority insolvency event with prolonged Corporate Insolvency Resolution Process (CIRP) ongoing since October 30, 2019, now exceeding 6 years without full resolution. NCLT approved JBVNL's acquisition resolution plan on December 17, 2024, but implementation remains stayed by NCLAT, leading to a deadlock in quarterly and annual statutory compliances for periods ended March 31, 2025. The erstwhile Compliance Officer, Harpreet Kaur Bhamra, cites inaction by Resolution Professional M. Anish Agarwal and Successful Resolution Applicant (JBVNL), compounded by inoperative company email and website. Negative sentiment prevails with 9/10 materiality, signaling severe governance and operational paralysis. No period-over-period financial comparisons, ratios, or operational metrics available due to insolvency stasis, highlighting zero growth or margin trends amid stagnation. Portfolio-level implication: single distressed manufacturing asset underscores risks in unresolved bankruptcies, advising avoidance for long-only investors. Critical market event flags potential delisting or further value erosion for shareholders.

1 high priority 1 total filings